TORONTO, ONTARIO--(Marketwired - Nov. 24, 2014) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of Proktis-M® suppositories.
Proktis-M® (sodium hyaluronate) rectal suppository is designed to help healing of the anus and rectum. Proktis-M® has been studied and tested in conditions such as operated severe internal hemorrhoids, anal fissures, and prevention of radiation induced proctitis.
Proktis-M® is formulated with sodium hyaluronate - a naturally occurring compound - and sets in place a temporary matrix to facilitate cell proliferation and thus enhancing wound healing. It can be used in combination with other products or alone to help on the above conditions. Proktis-M® is supported by clinical evidence, and has been successfully used to treat men and women in several European countries.
"The launch of Proktis-M® is yet another milestone in the development of the BioSyent Pharma business," commented René Goehrum, CEO of BioSyent. "Proktis-M® is our fifth marketed pharmaceutical product and represents a further broadening of our portfolio. We are also in full preparation for the launch of our sixth product in the first quarter of 2015."
Proktis-M® is approved by Health Canada and was in-licensed by BioSyent Pharma for exclusive marketing and distribution in Canada from FARMA-DERMA s.r.l., Italy in March of 2014.
To learn more about Proktis-M®, please visit the product website www.proktis-m.ca.
About BioSyent Inc.
Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.
Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.
At the date of this press release the Company had 13,851,195 shares issued and outstanding.
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.